Myomo (MYO) Expected to Announce Earnings on Wednesday

Myomo (NYSEAMERICAN:MYO) is expected to be releasing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Myomo to post earnings of ($0.12) per share and revenue of $9.24 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Myomo Price Performance

Shares of MYO stock opened at $0.90 on Monday. The stock’s 50 day simple moving average is $0.74 and its 200 day simple moving average is $0.86. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.93 and a current ratio of 3.30. Myomo has a twelve month low of $0.61 and a twelve month high of $4.99. The company has a market capitalization of $34.65 million, a price-to-earnings ratio of -2.43 and a beta of 1.39.

Insider Buying and Selling

In other Myomo news, Director Heather C. Getz bought 70,000 shares of the stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $0.73 per share, with a total value of $51,100.00. Following the acquisition, the director directly owned 111,754 shares of the company’s stock, valued at $81,580.42. This represents a 167.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Thomas F. Kirk bought 72,000 shares of the stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $0.71 per share, for a total transaction of $51,120.00. Following the acquisition, the director directly owned 553,857 shares in the company, valued at approximately $393,238.47. The trade was a 14.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 162,000 shares of company stock worth $116,220 in the last ninety days. Insiders own 4.54% of the company’s stock.

Institutional Trading of Myomo

Several institutional investors have recently bought and sold shares of MYO. Rosalind Advisors Inc. boosted its stake in Myomo by 33.0% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,595,788 shares of the company’s stock valued at $7,767,000 after buying an additional 892,127 shares in the last quarter. Geode Capital Management LLC raised its position in Myomo by 160.8% in the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock valued at $1,446,000 after purchasing an additional 412,631 shares during the last quarter. Centiva Capital LP bought a new position in Myomo in the 3rd quarter valued at $190,000. XTX Topco Ltd bought a new position in Myomo in the 4th quarter valued at $148,000. Finally, Nuveen LLC raised its position in Myomo by 66.4% in the 4th quarter. Nuveen LLC now owns 370,325 shares of the company’s stock valued at $337,000 after purchasing an additional 147,784 shares during the last quarter. Institutional investors and hedge funds own 44.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum reissued a “buy” rating on shares of Myomo in a research note on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo presently has an average rating of “Buy” and a consensus target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.